Boehringer Ingelheim
-
Warren Center for Neuroscience Drug Discovery researchers create new compound to potentially treat negative and positive symptoms of schizophrenia
We often think about diseases in terms of the symptoms they present. A cold might give you the sniffles or even GI distress, while malaria can give you fever, chills, or nausea... Read MoreJan 30, 2025
-
Vanderbilt-discovered cancer killing compound is now available through Boehringer Ingelheim open science portal opnMe
Researchers in the lab of Stephen Fesik, Orrin H. Ingram II Chair in Cancer Research, have added BI-0474 as the second molecule co-discovered by Vanderbilt to the open science portal opnMe.com, an initiative being driven by biopharmaceutical company Boehringer Ingelheim. Read MoreMay 30, 2024
-
Vanderbilt, Boehringer Ingelheim announce partnership to develop therapies for psychiatric disorders
Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia. Read MoreJan 3, 2019